Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Imaging
Published in: Cancer Imaging 1/2024

Open Access 01-12-2024 | Positron Emission Tomography | Review

Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers

Authors: Yuze Ma, Feng Gao

Published in: Cancer Imaging | Issue 1/2024

Login to get access

Abstract

GRPR is a type of seven-transmembrane G-protein coupled receptor that belongs to the bombesin protein receptor family. It is highly expressed in various cancers, including prostate cancer, breast cancer, lung cancer, gastrointestinal cancer, and so on. As a result, molecular imaging studies have been conducted using radiolabeled GRPR ligands for tumor diagnosis, as well as monitoring of recurrence and metastasis. In this paper, we provided a comprehensive overview of relevant literature from the past two decades, with a specific focus on the advancements made in radiolabeled GRPR ligands for imaging prostate cancer and breast cancer.
Literature
1.
Spindel ER, Giladi E, Brehm P, Goodman RH, Segerson TP. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol endocrinol (Baltimore, Md). 1990;4:1956–63.CrossRef
2.
Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008;15:58–64.PubMedPubMedCentralCrossRef
3.
Rozengurt E. Bombesin stimulation of mitogenesis Specific receptors, signal transduction, and early events. Am rev respir dis. 1990;142:S11-15.PubMedCrossRef
4.
Rozengurt E, Fabregat I, Coffer A, Gil J, Sinnett-Smith J. Mitogenic signalling through the bombesin receptor: role of a guanine nucleotide regulatory protein. J Cell Sci Suppl. 1990;13:43–56.PubMedCrossRef
5.
Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol rev. 2008;60:1–42.PubMedCrossRef
6.
Rouissi N, Rhaleb NE, Nantel F, Dion S, Drapeau G, Regoli D. Characterization of bombesin receptors in peripheral contractile organs. Br J Pharmacol. 1991;103:1141–7.PubMedPubMedCentralCrossRef
7.
Safavy A, Raisch KP, Matusiak D, Bhatnagar S, Helson L. Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide “scorpion” molecule. Bioconjug Chem. 2006;17:565–70.PubMedCrossRef
8.
Weber HC. Regulation and signaling of human bombesin receptors and their biological effects. Curr Opin Endocrinol Diabetes Obes. 2009;16:66–71.PubMedCrossRef
9.
Patel M, Kawano T, Suzuki N, Hamakubo T, Karginov AV, Kozasa T. Gα13/PDZ-RhoGEF/RhoA signaling is essential for gastrin-releasing peptide receptor-mediated colon cancer cell migration. Mol Pharmacol. 2014;86:252–62.PubMedPubMedCentralCrossRef
10.
E. Rozengurt, S. Guha, J. Sinnett-Smith, Gastrointestinal peptide signalling in health and disease.  Eur J Surg Suppl. 2002:(587):23-38.
11.
Patel O, Dumesny C, Giraud AS, Baldwin GS, Shulkes A. Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor. Biochem Pharmacol. 2004;68:2129–42.PubMedCrossRef
12.
Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol Metab. 2002;13:128–34.PubMedCrossRef
13.
Qu X, Xiao D, Weber HC. Human gastrin-releasing peptide receptor mediates sustained CREB phosphorylation and transactivation in HuTu 80 duodenal cancer cells. FEBS Lett. 2002;527:109–13.PubMedCrossRef
14.
Degen LP, Peng F, Collet A, Rossi L, Ketterer S, Serrano Y, Larsen F, Beglinger C, Hildebrand P. Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit. Gastroenterology. 2001;120:361–8.PubMedCrossRef
15.
Schubert ML, Hightower J, Coy DH, Makhlouf GM. Regulation of acid secretion by bombesin/GRP neurons of the gastric fundus. Am J Physiol. 1991;260:G156-160.PubMed
16.
Hildebrand P, Lehmann FS, Ketterer S, Christ AD, Stingelin T, Beltinger J, Gibbons AH, Coy DH, Calam J, Larsen F, Beglinger C. Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist. Gut. 2001;49:23–8.PubMedPubMedCentralCrossRef
17.
Pettersson M, Ahrén B. Gastrin releasing peptide (GRP): effects on basal and stimulated insulin and glucagon secretion in the mouse. Peptides. 1987;8:55–60.PubMedCrossRef
18.
De la Fuente M, Del Rio M, Ferrandez MD, Hernanz A. Modulation of phagocytic function in murine peritoneal macrophages by bombesin, gastrin-releasing peptide and neuromedin C. Immunology. 1991;73:205–11.PubMedPubMedCentral
19.
Del Rio M, De la Fuente M. Chemoattractant capacity of bombesin, gastrin-releasing peptide and neuromedin C is mediated through PKC activation in murine peritoneal leukocytes. Regul Pept. 1994;49:185–93.PubMedCrossRef
20.
Levine AS, Morley JE. Stress-induced eating in rats. Am J Physiol. 1981;241:R72-76.PubMed
21.
Kraly FS, Miller LA, Gibbs J. Diurnal variation for inhibition of eating by bombesin in the rat. Physiol Behav. 1983;31:395–9.PubMedCrossRef
22.
Roesler R, Luft T, Oliveira SH, Farias CB, Almeida VR, Quevedo J, Dal Pizzol F, Schröder N, Izquierdo I, Schwartsmann G. Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology. 2006;51:350–7.PubMedCrossRef
23.
Merali Z, McIntosh J, Kent P, Michaud D, Anisman H. Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala, The Journal of neuroscience : the official journal of the Society for. Neuroscience. 1998;18:4758–66.PubMedPubMedCentralCrossRef
24.
Brown MR, Gray TS. Peptide injections into the amygdala of conscious rats: effects on blood pressure, heart rate and plasma catecholamines. Regul Pept. 1988;21:95–106.PubMedCrossRef
25.
Shumyatsky GP, Tsvetkov E, Malleret G, Vronskaya S, Hatton M, Hampton L, Battey JF, Dulac C, Kandel ER, Bolshakov VY. Identification of a signaling network in lateral nucleus of amygdala important for inhibiting memory specifically related to learned fear. Cell. 2002;111:905–18.PubMedCrossRef
26.
Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Can Res. 1999;59:1152–9.
27.
Körner M, Waser B, Rehmann R, Reubi JC. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2014;74:217–24.PubMedCrossRef
28.
Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, Müntener M, Kristiansen G. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318–25.PubMedCrossRef
29.
30.
Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002;29:855–62.PubMedCrossRef
31.
Morgat C, MacGrogan G, Brouste V, Vélasco V, Sévenet N, Bonnefoi H, Fernandez P, Debled M, Hindié E. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2017;58:1401–7.CrossRef
32.
Dalm SU, Martens JW, Sieuwerts AM, van Deurzen CH, Koelewijn SJ, de Blois E, Maina T, Nock BA, Brunel L, Fehrentz JA, Martinez J, de Jong M, Melis M. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2015;56:752–7.CrossRef
33.
Mattei J, Achcar RD, Cano CH, Macedo BR, Meurer L, Batlle BS, Groshong SD, Kulczynski JM, Roesler R, Dal Lago L, Brunetto AT, Schwartsmann G. Gastrin-releasing peptide receptor expression in lung cancer. Arch Pathol Lab Med. 2014;138:98–104.PubMedCrossRef
34.
Reubi JC, Körner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31:803–10.PubMedCrossRef
35.
Reubi JC. Peptide receptor expression in GEP-NET. Virchows Archiv : an international journal of pathology. 2007;451(Suppl 1):S47-50.PubMedCrossRef
36.
Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6–14). Clinical cancer research : an official journal of the American Association for Cancer Research. 2002;8:1139–46.PubMed
37.
Bitar KN, Zhu XX. Expression of bombesin-receptor subtypes and their differential regulation of colonic smooth muscle contraction. Gastroenterology. 1993;105:1672–80.PubMedCrossRef
38.
Bartholdi MF, Wu JM, Pu H, Troncoso P, Eden PA, Feldman RI. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int J Cancer. 1998;79:82–90.PubMedCrossRef
39.
Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42:295–303.PubMedCrossRef
40.
Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer. 1989;63:1714–20.PubMedCrossRef
41.
Reile H, Armatis PE, Schally AV. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate. 1994;25:29–38.PubMedCrossRef
42.
Ehlers RA, Kim S, Zhang Y, Ethridge RT, Murrilo C, Hellmich MR, Evans DB, Townsend Jr CM, Mark Evers B. Gut peptide receptor expression in human pancreatic cancers. Ann Surg. 2000;231(6):838–48.PubMedPubMedCentralCrossRef
43.
Giacchetti S, Gauvillé C, de Crémoux P, Bertin L, Berthon P, Abita JP, Cuttitta F, Calvo F. Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer. 1990;46:293–8.PubMedCrossRef
44.
Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Can Res. 1995;55:280–7.
45.
Uchida K, Kojima A, Morokawa N, Tanabe O, Anzai C, Kawakami M, Eto Y, Yoshimura K. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol. 2002;128:633–40.PubMedCrossRef
46.
Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Hunt M, Wolfe T, Venkatraman ES, Jackson A, Skwarchuk M, Leibel SA. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2000;55:241–9.PubMedCrossRef
47.
Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:765–71.PubMedCrossRef
48.
Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, Gropler RJ, Knuuti J, Schelbert HR, Travin MI. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures, Journal of nuclear cardiology : official publication of the American Society of Nuclear. Cardiology. 2016;23:1187–226.
49.
50.
Satoh Y, Motosugi U, Imai M, Onishi H. Comparison of dedicated breast positron emission tomography and whole-body positron emission tomography/computed tomography images: a common phantom study. Ann Nucl Med. 2020;34:119–27.PubMedCrossRef
51.
Pichler V, Berroterán-Infante N, Philippe C, Vraka C, Klebermass EM, Balber T, Pfaff S, Nics L, Mitterhauser M, Wadsak W. An Overview of PET Radiochemistry, Part 1: The Covalent Labels (18)F, (11)C, and (13)N, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2018;59:1350–4.CrossRef
52.
Zhou Y, Baidoo KE, Brechbiel MW. Mapping biological behaviors by application of longer-lived positron emitting radionuclides. Adv Drug Deliv Rev. 2013;65:1098–111.PubMedCrossRef
53.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.PubMedCrossRef
54.
Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167:2435–9.PubMedCrossRef
55.
Elter M, Schulz-Wendtland R, Wittenberg T. The prediction of breast cancer biopsy outcomes using two CAD approaches that both emphasize an intelligible decision process. Med Phys. 2007;34:4164–72.PubMedCrossRef
56.
Marsouvanidis PJ, Nock BA, Hajjaj B, Fehrentz JA, Brunel L, M’Kadmi C, van der Graaf L, Krenning EP, Maina T, Martinez J, de Jong M. Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, (111)in-labeling, and preclinical profile. J Med Chem. 2013;56:2374–84.PubMedCrossRef
57.
Lucente E, Liu H, Liu Y, Hu X, Lacivita E, Leopoldo M, Cheng Z. Novel (64)Cu Labeled RGD(2)-BBN Heterotrimers for PET Imaging of Prostate Cancer. Bioconjug Chem. 2018;29:1595–604.PubMedCrossRef
58.
Yang YS, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol. 2006;33:371–80.PubMedCrossRef
59.
Maina T, Nock B, Mather S. Targeting prostate cancer with radiolabelled bombesins. Cancer imaging : the official publication of the International Cancer Imaging Society. 2006;6:153–7.PubMedCrossRef
60.
Yu Z, Ananias HJ, Carlucci G, Hoving HD, Helfrich W, Dierckx RA, Wang F, de Jong IJ, Elsinga PH. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des. 2013;19:3329–41.PubMedCrossRef
61.
Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC. Bombesin receptor antagonists may be preferable to agonists for tumor targeting, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2008;49:318–26.CrossRef
62.
Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides, Clinical cancer research : an official journal of the American Association for. Can Res. 2009;15:5240–9.
63.
Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97–107.PubMedCrossRef
64.
Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, Groen HC, Reneman S, de Blois E, Breeman WA, de Jong M. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging. 2011;38(7):1257–66.PubMedPubMedCentralCrossRef
65.
Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2011;52:470–7.CrossRef
66.
Tokita K, Katsuno T, Hocart SJ, Coy DH, Llinares M, Martinez J, Jensen RT. Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor. J Biol Chem. 2001;276:36652–63.PubMedCrossRef
67.
Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2014;55:2050–6.CrossRef
68.
Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, Nock BA, de Jong M, Baum RP. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:964–73.PubMedCrossRef
69.
Bakker IL, Fröberg AC, Busstra MB, Verzijlbergen JF, Konijnenberg M, van Leenders G, Schoots IG, de Blois E, van Weerden WM, Dalm SU, Maina T, Nock BA, de Jong M. GRPr Antagonist (68)Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2021;62:1517–23.CrossRef
70.
Mitran B, Thisgaard H, Rosenström U, Dam JH, Larhed M, Tolmachev V, Orlova A. High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. Contrast Media Mol Imaging. 2017;2017:6873684.PubMedPubMedCentralCrossRef
71.
Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, Wu H, Zhu Z, Li F, Chen X. PET Using a GRPR Antagonist (68)Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2018;59:922–8.CrossRef
72.
Wang L, Zhang Z, Merkens H, Zeisler J, Zhang C, Roxin A, Tan R, Bénard F, Lin KS. (68)Ga-Labeled [Leu(13)ψThz(14)]Bombesin(7–14) Derivatives: Promising GRPR-Targeting PET Tracers with Low Pancreas Uptake. Molecules (Basel, Switzerland). 2022;27:3777.PubMedPubMedCentralCrossRef
73.
Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, Bladou F, Benard A, Hindie E, Gallerande HC, Morgat C. Comparison of (68)Ga-PSMA-617 PET/CT and (68)Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2023;64:379–85.CrossRef
74.
Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007;101:175–83.PubMedCrossRef
75.
Liu Z, Yan Y, Liu S, Wang F, Chen X. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2009;20:1016–25.PubMedPubMedCentralCrossRef
76.
Van de Wiele C, Phonteyne P, Pauwels P, Goethals I, Van den Broecke R, Cocquyt V, Dierckx RA. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2008;49:260–4.CrossRef
77.
Ferguson S, Wuest M, Richter S, Bergman C, Dufour J, Krys D, Simone J, Jans HS, Riauka T, Wuest F. A comparative PET imaging study of (44g)Sc- and (68)Ga-labeled bombesin antagonist BBN2 derivatives in breast and prostate cancer models. Nucl Med Biol. 2020;90–91:74–83.PubMedCrossRef
78.
Stoykow C, Erbes T, Maecke HR, Bulla S, Bartholomä M, Mayer S, Drendel V, Bronsert P, Werner M, Gitsch G, Weber WA, Stickeler E, Meyer PT. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET. Theranostics. 2016;6:1641–50.PubMedPubMedCentralCrossRef
79.
Kaloudi A, Lymperis E, Giarika A, Dalm S, Orlandi F, Barbato D, Tedesco M, Maina T, de Jong M, Nock BA. NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [(67)Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice. Molecules. 2017;22(11):1950.PubMedPubMedCentralCrossRef
80.
Dalm SU, Sieuwerts AM, Look MP, Melis M, van Deurzen CH, Foekens JA, de Jong M, Martens JW. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy, Journal of nuclear medicine : official publication, Society of. Nuclear Medicine. 2015;56:1487–93.CrossRef
81.
Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat. 2005;92:175–86.PubMedCrossRef
82.
Prignon A, Nataf V, Provost C, Cagnolini A, Montravers F, Gruaz-Guyon A, Lantry LE, Talbot JN, Nunn AD. (68)Ga-AMBA and (18)F-FDG for preclinical PET imaging of breast cancer: effect of tamoxifen treatment on tracer uptake by tumor. Nucl Med Biol. 2015;42:92–8.PubMedCrossRef
83.
Dalm SU, Schrijver WA, Sieuwerts AM, Look MP, Ziel-van der Made AC, de Weerd V, Martens JW, van Diest PJ, de Jong M, van Deurzen CH. Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE. 2017;12: e0170536.PubMedPubMedCentralCrossRef
84.
Zhang J, Mao F, Niu G, Peng L, Lang L, Li F, Ying H, Wu H, Pan B, Zhu Z, Chen X. (68)Ga-BBN-RGD PET/CT for GRPR and Integrin α(v)β(3) Imaging in Patients with Breast Cancer. Theranostics. 2018;8:1121–30.PubMedPubMedCentralCrossRef
85.
Morgat C, Schollhammer R, Macgrogan G, Barthe N, Velasco V, Vimont D, Cazeau AL, Fernandez P, Hindie E. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PLoS ONE. 2019;14: e0210905.PubMedPubMedCentralCrossRef
86.
Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol. 1999;276:G655-665.PubMed
87.
Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2002;94:375–83.PubMedCrossRef
88.
Metadata
Title
Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers
Authors
Yuze Ma
Feng Gao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2024
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-024-00658-y

Other articles of this Issue 1/2024

Cancer Imaging 1/2024 Go to the issue

Research article

Prognostic value of CT-based radiomics in grade 1–2 pancreatic neuroendocrine tumors

Research article

Automated segmentation of lesions and organs at risk on [68Ga]Ga-PSMA-11 PET/CT images using self-supervised learning with Swin UNETR

Research article

A clinical-radiomics nomogram based on dual-layer spectral detector CT to predict cancer stage in pancreatic ductal adenocarcinoma

Research article

Preoperative prediction of early recurrence in resectable pancreatic cancer integrating clinical, radiologic, and CT radiomics features

Research article

Development of a modified 3D region proposal network for lung nodule detection in computed tomography scans: a secondary analysis of lung nodule datasets

Research article

Applying dynamic contrast-enhanced MRI tracer kinetic models to differentiate benign and malignant soft tissue tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits